BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life
RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms among young children initiating berotralstat in the APeX-P trial, and the broad safety and efficacy outcomes observed across all age groups of patients taking ORLADEYO to prevent HAE attacks.
'These data underscore the potential of our oral, once-daily prophylactic treatment to deliver consistent, meaningful benefits for people living with HAE across all stages of life. From young children to adolescents and adults, ORLADEYO continues to show strong efficacy and tolerability, helping patients experience more days free from attacks. These clinical and real-world results give me confidence that we can continue to have a very positive impact on advancing care for all those living with HAE, regardless of their age,' said Helen Thackray, chief research and development officer at BioCryst.
The following three studies are being presented at the 14th C1-Inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary from May 29–June 1, 2025.
Reduction in Percentage of Days with Angioedema Symptoms Among Young Children Initiating Berotralstat – Interim Results from ApeX-P
Oral Presentation - Session IV - Saturday, May 31 - 10:30 – 12:45 (12:00-12:15)
The ongoing open-label APeX-P study is evaluating berotralstat in children aged 2 to 11 years with HAE. There were four weight-based cohorts. Cohort 1 from these interim results received 150 mg capsules daily, while cohorts 2–4 received daily oral granule doses of 108, 96, and 78 mg, respectively. The median age was 8 years (range: 3–11), with disease onset typically between ages 2–6 years. Prior to enrollment, patients reported a mean (SD) of 18.0 (20.5) missed school days annually due to HAE. While on berotralstat, at least half of patients were attack-free each month. The percentage of days with angioedema symptoms dropped from a mean (SD) of 11 percent (9.4 percent) during the standard-of-care period, measured pre-study, to 4.0 percent (4.7 percent) over 12 weeks, with this improvement sustained up to 48 weeks. The most common treatment emergent adverse events (TEAEs) were nasopharyngitis, upper respiratory tract infection and headache. These interim findings suggest berotralstat may help children with HAE experience fewer symptoms and a more normal daily life.
Berotralstat for the Prevention of Hereditary Angioedema Attacks: Results from the Italian Expanded Access Program
Oral Presentation - Session VI- Sunday, June 1 - 08:00 – 09:30 (09:00-09:15)
In the Italian expanded access program (EAP), 22 patients received berotralstat free of charge until commercial availability, with an additional 12 weeks of treatment to ensure continuity. Safety was monitored throughout, and data on breakthrough attacks, disease control, and quality of life (QoL) were collected.
Among 12 patients with available data, median (mean) Angioedema Control Test (AECT) scores improved from 11.5 (12.8) at baseline to 13.0 (14.0) at month three and 16.0 (14.8) at month six, indicating better disease control. Median (mean) AE-QoL total scores decreased from 45.0 (42.3) at baseline to 40.0 (37.6) at month three and 36.2 (34.0) at month six, reflecting clinically meaningful improvements in QoL.
All 15 patients still enrolled at program closure transitioned to commercially available ORLADEYO. The treatment was associated with a consistently low HAE attack rate, improved disease control and a safety profile consistent with clinical trial findings.
Tolerability and Effectiveness of Berotralstat for Prophylaxis in Adolescents with Hereditary Angioedema: subgroup analysis of the Berolife Study
Oral Presentation - Session VI - Sunday June 1 – 08:00-9:30 (08:30-08:45)
The Berolife study, a real-world observational study in France, assessed the tolerability and effectiveness of berotralstat in patients with HAE, including a subgroup of adolescents (aged 12–17) who received 150 mg once daily.
The mean (SD) baseline attack rate was 1.8 (1.1) attacks/month (median: 1.8), based on the six months prior to enrolment. After six months of treatment, the median monthly attack rate decreased to 0.55 (from 2.25 at baseline), with similar reductions sustained at 12 and 18 months. TEAEs in adolescents were consistent with those seen in the overall Berolife population and in the APeX-2 and APeX-S clinical trials.
These findings support berotralstat as an effective and well-tolerated long-term prophylactic option for adolescents with HAE.
About ORLADEYO® (berotralstat)ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
U.S. Indication and Important Safety InformationINDICATIONORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.
IMPORTANT SAFETY INFORMATION
An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.
The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.
A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C).
Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers (eg, rifampin, St. John's wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.
ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.
The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.
There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.
To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements and statements relating to ORLADEYO performance and effectiveness. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; interim results of a clinical trial do not necessarily predict final results; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay, or withdraw market approval for products and product candidates; and BioCryst's ability to successfully manage its growth and compete effectively. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859 7910jbluth@biocryst.com
Niamh Lyons +353 87 7745000nlyons@biocryst.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Martini Market Presale Surpasses 40% of Softcap Within 24 Hours of Launch on XRP Ledger
By GlobeNewswire Published on June 21, 2025, 19:02 IST DUBAI, United Arab Emirates, June 21, 2025 (GLOBE NEWSWIRE) — Martini Market , the decentralized prediction market platform being developed on the XRP Ledger (XRPL), has confirmed that its $MRT token presale has exceeded 40% of its initial softcap target within 24 hours of launch. The strong early participation reflects rising interest in emerging use cases within the expanding XRP ecosystem. The presale, which opened on June 19 at 3 PM UTC, offers 4 million $MRT tokens to the public out of a total supply of 10 million. The softcap is set at 50,000 XRP, and the hardcap is capped at 250,000 XRP. According to the project team, over 20,000 XRP has already been contributed in the first 24 hours. Martini Market positions itself as the first decentralized, on-chain prediction platform built directly on the XRP Ledger. It aims to enable users to create and participate in outcome-based markets tied to real-world events. These include sectors such as politics, sports, finance, and global affairs, resolved via oracles and on-chain automation. The $MRT token is designed as a core utility asset within the Martini Market ecosystem. According to the team, its intended functions include governance participation, staking, and market creation. Platform users holding specific quantities of $MRT will have access to additional roles and benefits once the platform is live. The project launch comes amid a period of notable development across the XRP Ledger. Ripple's recent regulatory progress in the UAE, including DFSA approval and partnerships with Zand Bank and Mamo, along with the integration of USDC and RLUSD, and the introduction of an EVM-compatible sidechain, have contributed to an environment increasingly supportive of DeFi protocols. 'The early demand for $MRT appears to reflect an appetite within the XRPL community for decentralized tools that go beyond payments,' said a Martini Market spokesperson. 'Prediction markets are widely used on other blockchains, and bringing this functionality to XRPL could open a new chapter in its utility-driven growth.' The $MRT token is currently being offered at a presale rate of 1 XRP = 16 MRT. Post-presale, the listing price has been set at 1 XRP = 11 MRT, representing a difference of approximately 30% from the presale valuation. The presale is expected to run for up to 30 days, though it may conclude earlier if the hardcap is reached. In addition to governance and market participation, $MRT will also be used to incentivize liquidity providers and potentially reward staking participants. Specific platform mechanisms will be detailed further as the protocol approaches mainnet deployment. Martini Market has not made any financial projections or investment claims regarding $MRT. The team emphasizes that participation in the presale is subject to personal discretion and recommends that users conduct independent research before contributing. For more information on Martini Market's presale structure, roadmap, or token details, users are encouraged to visit the official website and verified community channels. Official ChannelsWebsite: @MartiniXRPLTelegram: Discord: Contact:Picard Beaumont [email protected] Disclaimer: This is a paid post and is provided by Martini Market. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector–including cryptocurrency, NFTs, and mining–complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
4 hours ago
- Business Upturn
How to participate in Quid Miner cloud mining and earn passive income every day using XRP or DOGE
Boston, Massachusetts, June 21, 2025 (GLOBE NEWSWIRE) — In the dynamic cryptocurrency market, XRP and DOGE have always attracted much attention. XRP, with its advantages in the field of cross-border payments, is seen as a bridge connecting traditional finance and blockchain; and DOGE has quickly become popular and a market hotspot relying on its strong community support and star effect. As the market gradually becomes standardized and supervision is strengthened, the development directions of the two cryptocurrencies have begun to diverge significantly. The latest data shows that after a round of strong growth, XRP's price is currently trading sideways in a key range, and market momentum has slowed down. At the same time, DOGE's technical side is weak and faces pullback pressure in the short term. Despite this, some large investors continue to increase their positions in DOGE, indicating that its long-term prospects are still optimistic. In the current market environment, more and more investors are beginning to seek more stable and sustainable ways to return. At this time, the launch of QuidMiner provides them with a new option. Providing potential cryptocurrency mining solutions to investors Quid Miner was founded in 2010 and is headquartered in the UK. It is a regulated cloud mining platform that serves more than 8 million users in more than 180 countries around the world. Quid Miner deeply integrates artificial intelligence and green renewable energy and applies them to the cloud mining field. Quid Miner is committed to making cloud mining simple, efficient and safe. Relying on advanced technology and a global network of data centers,Quid Miner allows users to easily participate in the blockchain ecosystem and earn potential passive income without having to purchase hardware or maintain equipment. QuidMiner platform core advantages: ⦁ Register and log in to get a $15 reward (a daily $0.60 sign-in bonus) ⦁ Simple interface and convenient operation: all fee structures are fully open and transparent, without any hidden fees. Provide a variety of flexible contract options ⦁ The platform supports more than 10 cryptocurrencies for settlement (recharge and withdrawal): including DOGE, BTC, ETH, SOL, BCH, XRP, USDC, LTC, USDT-TRC20 and USDT-ERC20, etc. ⦁ Referral Affiliate Program: Recommend your friends to register and you will receive referral bonus permanently. ⦁ Relying on the dual protection of McAfee® and Cloudflare®, it provides stable operation support and 7×24 hours of real-time technical customer service to ensure user safety. Start your mining journey in 3 simple steps ⦁Visit the official website of quidminer and register as a member immediately via email. ⦁Choose a mining contract that suits your budget and start your mining plan easily. ⦁Referral Affiliate Program: Refer friends to register and get potential referral rewards Learn about QuidMiner mining contracts and explore new ways to manage digital assets (Note:Please configure flexibly and reasonably according to your own budget and choose a variety of contracts that suit you. You will have the opportunity to obtain potential profits. Your potential profits will be automatically calculated and settled in your account.) In summary As the uncertainty in the cryptocurrency market intensifies, QuidMiner has attracted more and more users' attention with its advanced security technology architecture features, compliant and transparent operating system, and simple and intuitive user experience. Whether you are a beginner or a seasoned veteran investor,QuidMiner provides you with a potential passive income solution. For more information, please visit the official website of the platform: APP application download Official platform email: [email protected] Disclaimer: The information provided in this press release is not a solicitation to invest and is not intended as investment advice, financial advice, or trading advice. Cryptocurrency mining and staking involve risks. There is a possibility of loss of funds. You are strongly advised to perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
4 hours ago
- Business Upturn
AIXA Miner Unveils New Free Cloud Mining Platform Aligned with 2025 Green Tech and Smart Mining Goals
Denver, CO, USA, June 21, 2025 (GLOBE NEWSWIRE) — In a strategic move that highlights its commitment to innovation and environmental responsibility, AIXA Miner has announced the launch of its upgraded free cloud mining platform, designed for a new generation of crypto users. The announcement aligns with the growing industry focus on sustainability, smart mining technologies, and secure digital asset access, making AIXA one of the first platforms to truly meet 2025's evolving mining standards. With a user base spanning over 120 countries and a strong foundation in automated mining infrastructure, AIXA Miner enables users to mine Bitcoin, Ethereum, and other top digital assets directly from the cloud — no hardware, no technical know-how required. A More Responsible Way to Mine Crypto The 2025 crypto mining landscape is shifting rapidly. Rising concerns about energy use, network security, and environmental impact have led many miners and investors to seek alternatives to traditional hardware mining. AIXA Miner is answering that call by launching a zero-cost, carbon-conscious, and technology-forward mining platform that removes entry barriers and prioritizes both profitability and planet. Key features of the new platform include: Free mining startup trial , available to all new users , available to all new users No hardware required , mining runs via AIXA's secured cloud infrastructure , mining runs via AIXA's secured cloud infrastructure Green energy-powered data centers AI-optimized mining schedules for efficiency and speed for efficiency and speed User dashboard with real-time earnings tracking Daily payouts in USDT or crypto of choice Technological Excellence Meets Everyday Usability What sets AIXA Miner apart is its ability to blend technical innovation with everyday simplicity. The platform's mining engine is backed by AI-driven algorithms and secure server farms — yet the interface is clean, user-friendly, and mobile-responsive. Users can start mining within minutes, with just an email sign-up and zero upfront investment. The platform also offers a selection of low-entry contracts for users looking to scale up at their own pace, along with a tiered referral system to encourage community growth. Sustainability Built In AIXA Miner's infrastructure includes green-compliant energy use policies and carbon-reduction initiatives, contributing to a smarter and more sustainable crypto ecosystem. This commitment not only meets the benchmarks outlined in global crypto mining sustainability frameworks for 2025, it also reflects the values of the growing number of eco-conscious digital asset users worldwide. How to Get Started Visit Sign up with your email to activate the free mining trial Choose your preferred asset and let the cloud engine begin mining Track your earnings daily and withdraw or reinvest as desired Invite others and earn referral rewards on every new user About AIXA Miner Founded in 2020, AIXA Miner is a U.S.-based cloud mining platform powered by renewable energy and artificial intelligence. With a presence in over 200 countries and regulatory certifications, the platform delivers secure, daily-yield mining services that are easy to access and designed for long-term sustainability. For more information, visit: [ Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
